Keros Therapeutics, Inc. $KROS Stock Position Reduced by SG Americas Securities LLC

SG Americas Securities LLC lessened its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 90.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 9,135 shares of the company’s stock after selling 89,568 shares during the quarter. SG Americas Securities LLC’s holdings in Keros Therapeutics were worth $101,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Financial Management Professionals Inc. acquired a new stake in shares of Keros Therapeutics during the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after acquiring an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Keros Therapeutics during the fourth quarter worth $212,000. Finally, New York State Common Retirement Fund boosted its position in Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $11.10 on Tuesday. The company has a market capitalization of $219.67 million, a price-to-earnings ratio of -3.69 and a beta of 0.97. Keros Therapeutics, Inc. has a one year low of $9.69 and a one year high of $22.55. The company’s fifty day moving average price is $10.96 and its two-hundred day moving average price is $13.58.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The company had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Weiss Ratings downgraded Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Keros Therapeutics currently has an average rating of “Hold” and a consensus target price of $20.40.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, Director Nima Farzan sold 2,625 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. This represents a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the transaction, the director owned 9,767 shares in the company, valued at approximately $104,702.24. This trade represents a 21.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 8,425 shares of company stock valued at $89,994. Corporate insiders own 12.60% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.